Literature DB >> 33686949

Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system.

Qiliang Peng1,2, Yi Shen3, Kai Fu4, Zheng Dai4, Lu Jin4, Dongrong Yang4, Jin Zhu4.   

Abstract

We developed and validated a new prognostic model for predicting the overall survival in clear cell renal cell carcinoma (ccRCC) patients. In this study, artificial intelligence (AI) algorithms including random forest and neural network were trained to build a molecular prognostic score (mPS) system. Afterwards, we investigated the potential mechanisms underlying mPS by assessing gene set enrichment analysis, mutations, copy number variations (CNVs) and immune cell infiltration. A total of 275 prognosis-related genes were identified, which were also differentially expressed between ccRCC patients and healthy controls. We then constructed a universal mPS system that depends on the expression status of only 21 of these genes by applying AI-based algorithms. Then, the mPS were validated by another independent cohort and demonstrated to be applicable to ccRCC subsets. Furthermore, a nomogram comprising the mPS score and several independent variables was established and proved to effectively predict ccRCC patient prognosis. Finally, significant differences were identified regarding the pathways, mutated genes, CNVs and tumor-infiltrating immune cells among the subgroups of ccRCC stratified by the mPS system. The AI-based mPS system can provide critical prognostic prediction for ccRCC patients and may be useful to inform treatment and surveillance decisions before initial intervention.

Entities:  

Keywords:  artificial intelligence; clear cell renal cell carcinoma; prognosis; scoring system

Year:  2021        PMID: 33686949      PMCID: PMC7993746          DOI: 10.18632/aging.202594

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  56 in total

Review 1.  Survival analysis and Cox regression.

Authors:  N Benítez-Parejo; M M Rodríguez del Águila; S Pérez-Vicente
Journal:  Allergol Immunopathol (Madr)       Date:  2011-10-19       Impact factor: 1.667

Review 2.  Copy Number Variation in Domestication.

Authors:  Zoe N Lye; Michael D Purugganan
Journal:  Trends Plant Sci       Date:  2019-02-08       Impact factor: 18.313

Review 3.  Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Authors:  Jacob J Adashek; Meghan M Salgia; Edwin M Posadas; Robert A Figlin; Jun Gong
Journal:  Clin Genitourin Cancer       Date:  2019-01-15       Impact factor: 2.872

Review 4.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

5.  Visualizing and interpreting cancer genomics data via the Xena platform.

Authors:  Mary J Goldman; Brian Craft; Mim Hastie; Kristupas Repečka; Fran McDade; Akhil Kamath; Ayan Banerjee; Yunhai Luo; Dave Rogers; Angela N Brooks; Jingchun Zhu; David Haussler
Journal:  Nat Biotechnol       Date:  2020-06       Impact factor: 54.908

Review 6.  Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.

Authors:  Helai P Mohammad; Olena Barbash; Caretha L Creasy
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

7.  Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.

Authors:  Beatrice Aramini; Christian Casali; Alessandro Stefani; Stefania Bettelli; Susanne Wagner; Zaina Sangale; Elisha Hughes; Jerry S Lanchbury; Antonino Maiorana; Uliano Morandi
Journal:  Lung Cancer       Date:  2016-09-06       Impact factor: 5.705

Review 8.  Biomarker-Guided Development of DNA Repair Inhibitors.

Authors:  James M Cleary; Andrew J Aguirre; Geoffrey I Shapiro; Alan D D'Andrea
Journal:  Mol Cell       Date:  2020-05-26       Impact factor: 17.970

Review 9.  Machine intelligence in peptide therapeutics: A next-generation tool for rapid disease screening.

Authors:  Shaherin Basith; Balachandran Manavalan; Tae Hwan Shin; Gwang Lee
Journal:  Med Res Rev       Date:  2020-01-10       Impact factor: 12.944

Review 10.  Tumor mutation burden: from comprehensive mutational screening to the clinic.

Authors:  Francesca Galuppini; Carlo Alberto Dal Pozzo; Matteo Fassan; Raffaele Baffa; Jutta Deckert; Fotios Loupakis
Journal:  Cancer Cell Int       Date:  2019-08-07       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.